{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T17:31:16Z","timestamp":1793640676488,"version":"4.5.1"},"reference-count":38,"publisher":null,"issue":"7","license":[{"start":{"date-parts":[[2022,7,31]],"date-time":"2022-07-31T00:00:00Z","timestamp":1659225600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/lib.ossn.ru\/jour\/about\/editorialPolicies#openAccessPolicy"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Kardiologiia"],"DOI":"10.18087\/cardio.2022.7.n2233","type":"journal-article","created":{"date-parts":[[2022,8,22]],"date-time":"2022-08-22T09:53:02Z","timestamp":1661161982000},"page":"3-11","source":"Crossref","is-referenced-by-count":0,"title":["Three ages of spironolactone. Evolution of views on spironolactone capabilities in the treatment of patients with heart failure."],"prefix":"10.68900","volume":"62","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4369-1393","authenticated-orcid":true,"given":"F. T.","family":"Ageev","sequence":"first","affiliation":[{"name":"Federal State Budgetary Institution NATIONAL MEDICAL RESEARCH CENTRE OF CARDIOLOGY NAMED AFTER ACADEMICIAN E.I.CHAZOV. Of the Ministry of Health of the Russian Federation"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":null,"published-online":{"date-parts":[[2022,7,31]]},"reference":[{"key":"ref1","unstructured":"Conn JW. Presidential address. I. Painting background. II. Primary aldosteronism, a new clinical syndrome. The Journal of Laboratory and Clinical Medicine. 1955;45(1):3\u201317. PMID: 13233623"},{"key":"ref2","doi-asserted-by":"crossref","unstructured":"Wehling M, Eisen C, Christ M. Aldosterone-specific membrane receptors and rapid non-genomic actions of mineralocorticoids. Molecular and Cellular Endocrinology. 1992;90(1):C5\u20139. DOI: 10.1016\/0303-7207(92)90092-K","DOI":"10.1016\/0303-7207(92)90092-K"},{"key":"ref3","unstructured":"Goncharov P.P. Aldosterone and cardiovascular function (to the 50th anniversary of the discovery of aldosterone). Problems of Endocrinology. 2004;50(6):29\u201332. DOI: 10.14341\/probl11621"},{"key":"ref4","doi-asserted-by":"crossref","unstructured":"Garg R, Yusuf S. Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. Collaborative Group on ACE Inhibitor Trials. JAMA. 1995;273(18):1450\u20136","DOI":"10.1001\/jama.273.18.1450"},{"key":"ref5","doi-asserted-by":"crossref","unstructured":"Braunwald E. ACE Inhibitors \u2013 A Cornerstone of the Treatment of Heart Failure. New England Journal of Medicine. 1991;325(5):351\u20133. DOI: 10.1056\/NEJM199108013250508","DOI":"10.1056\/NEJM199108013250508"},{"key":"ref6","unstructured":"Mareev V.Yu., Skvortsov \u0410.\u0410., Chelmakina S.M. Are angiotensin converting enzyme inhibitors able to effectively control the activity of the renin-angiotensin-aldosterone system in the long-term treatment of chronic heart failure? Kardiologiia. 1999;39(2):27\u2013 34."},{"key":"ref7","doi-asserted-by":"crossref","unstructured":"Staessen J, Lijnen P, Fagard R, Verschueren LJ, Amery A. Rise in plasma concentration of aldosterone during long-term angiotensin II suppression. Journal of Endocrinology. 1981;91(3):457\u201365. DOI: 10.1677\/joe.0.0910457","DOI":"10.1677\/joe.0.0910457"},{"key":"ref8","unstructured":"Skvortsov A.A. Antagonists of mineralocorticoid receptors in the treatment of patients with chronic heart failure and myocardial infarction: a modern view of the old problem. Russian Medical Journal. 2017;25(4):257\u201364."},{"key":"ref9","doi-asserted-by":"crossref","unstructured":"Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A et al. The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure. New England Journal of Medicine. 1999;341(10):709\u201317. DOI: 10.1056\/NEJM199909023411001","DOI":"10.1056\/NEJM199909023411001"},{"key":"ref10","doi-asserted-by":"crossref","unstructured":"Vardeny O, Claggett B, Anand I, Rossignol P, Desai AS, Zannad F et al. Incidence, Predictors, and Outcomes Related to Hypo- and Hyperkalemia in Patients with Severe Heart Failure Treated with a Mineralocorticoid Receptor Antagonist. Circulation: Heart Failure. 2014;7(4):573\u20139. DOI: 10.1161\/CIRCHEARTFAILURE.114.001104","DOI":"10.1161\/CIRCHEARTFAILURE.114.001104"},{"key":"ref11","doi-asserted-by":"crossref","unstructured":"Pitt B, Gheorghiade M, Zannad F, Anderson JL, van Veldhuisen DJ, Parkhomenko A et al. Evaluation of eplerenone in the subgroup of EPHESUS patients with baseline left ventricular ejection fraction \u226430%. European Journal of Heart Failure. 2006;8(3):295\u2013301. DOI: 10.1016\/j.ejheart.2005.11.008","DOI":"10.1016\/j.ejheart.2005.11.008"},{"key":"ref12","doi-asserted-by":"crossref","unstructured":"Zannad F, McMurray JJV, Krum H, van Veldhuisen DJ, Swedberg K, Shi H et al. Eplerenone in Patients with Systolic Heart Failure and Mild Symptoms. New England Journal of Medicine. 2011;364(1):11\u2013 21. DOI: 10.1056\/NEJMoa1009492","DOI":"10.1056\/NEJMoa1009492"},{"key":"ref13","doi-asserted-by":"crossref","unstructured":"Chatterjee S, Moeller C, Shah N, Bolorunduro O, Lichstein E, Moskovits N et al. Eplerenone Is Not Superior to Older and Less Expensive Aldosterone Antagonists. The American Journal of Medicine. 2012;125(8):817\u201325. DOI: 10.1016\/j.amjmed.2011.12.018","DOI":"10.1016\/j.amjmed.2011.12.018"},{"key":"ref14","doi-asserted-by":"crossref","unstructured":"Vizzardi E, Nodari S, Caretta G, D\u2019Aloia A, Pezzali N, Faden G et al. Effects of spironolactone on long-term mortality and morbidity in patients with heart failure and mild or no symptoms. The American Journal of the Medical Sciences. 2014;347(4):271\u20136. DOI: 10.1097\/MAJ.0b013e31829dd6b1","DOI":"10.1097\/MAJ.0b013e31829dd6b1"},{"key":"ref15","doi-asserted-by":"crossref","unstructured":"Juurlink DN, Mamdani MM, Lee DS, Kopp A, Austin PC, Laupacis A et al. Rates of Hyperkalemia after Publication of the Randomized Aldactone Evaluation Study. New England Journal of Medicine. 2004;351(6):543\u201351. DOI: 10.1056\/NEJMoa040135","DOI":"10.1056\/NEJMoa040135"},{"key":"ref16","doi-asserted-by":"crossref","unstructured":"The treatment of heart failure. The Task Force of the Working Group on Heart Failure of the European Society of Cardiology. European Heart Journal. 1997;18(5):736\u201353. DOI: 10.1093\/oxfordjournals.eurheartj.a015339","DOI":"10.1093\/oxfordjournals.eurheartj.a015339"},{"key":"ref17","doi-asserted-by":"crossref","unstructured":"Remme W. Guidelines for the diagnosis and treatment of chronic heart failure. European Heart Journal. 2001;22(17):1527\u201360. DOI: 10.1053\/euhj.2001.2783","DOI":"10.1053\/euhj.2001.2783"},{"key":"ref18","doi-asserted-by":"crossref","unstructured":"Swedberg K, Cleland J, Dargie H, Drexler H, Follath F, Komajda M et al. Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005). European Heart Journal. 2005;26(11):1115\u201340. DOI: 10.1093\/eurheartj\/ehi204","DOI":"10.1093\/eurheartj\/ehi204"},{"key":"ref19","doi-asserted-by":"crossref","unstructured":"Dickstein K, Cohen-Solal A, Filippatos G, McMurray JJV, Ponikowski P, Poole-Wilson PA et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). European Heart Journal. 2008;29(19):2388\u2013442. DOI: 10.1093\/eurheartj\/ehn309","DOI":"10.1093\/eurheartj\/ehn309"},{"key":"ref20","doi-asserted-by":"crossref","unstructured":"McMurray JJV, Adamopoulos S, Anker SD, Auricchio A, Bohm M, Dickstein K et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. European Heart Journal. 2012;33(14):1787\u2013847. DOI: 10.1093\/eurheartj\/ehs104","DOI":"10.1093\/eurheartj\/ehs104"},{"key":"ref21","doi-asserted-by":"crossref","unstructured":"McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, B\u00f6hm M et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. European Heart Journal. 2021;42(36):3599\u2013726. DOI: 10.1093\/eurheartj\/ehab368","DOI":"10.1093\/eurheartj\/ehab368"},{"key":"ref22","doi-asserted-by":"crossref","unstructured":"Polyakov D.S., Fomin I.V., Belenkov Yu.N., Mareev V.Yu., Ageev F.T., Artemjeva E.G. et al. Chronic heart failure in the Russian Federation: what has changed over 20 years of follow-up? Results of the EPOCHCHF study. Kardiologiia. 2021;61(4):4\u201314. DOI: 10.18087\/cardio.2021.4.n1628","DOI":"10.18087\/cardio.2021.4.n1628"},{"key":"ref23","doi-asserted-by":"crossref","unstructured":"Oshchepkova E.V., Lazareva N.V., Satlykova D.F., Tereshchenko S.N. The first results of the Russian register of chronic heart failure. Kardiologiia. 2015;55(5):22\u20138.","DOI":"10.18565\/cardio.2015.5.22-28"},{"key":"ref24","doi-asserted-by":"crossref","unstructured":"Ageev F.T., Ovchinnikov A.G. Treatment of patients with heart failure and preserved ejection fraction: reliance on clinical phenotypes. Kardiologiia. 2022;62(7):1\u201310. DOI: 10.18087\/cardio.2022.7.n2058","DOI":"10.18087\/cardio.2022.7.n2058"},{"key":"ref25","doi-asserted-by":"crossref","unstructured":"Cleland JGF, Tendera M, Adamus J, Freemantle N, Gray CS, Lye M et al. Perindopril for elderly people with chronic heart failure: the PEP-CHF study. European Journal of Heart Failure. 1999;1(3):211\u20137. DOI: 10.1016\/S1388-9842(99)00039-2","DOI":"10.1016\/S1388-9842(99)00039-2"},{"key":"ref26","doi-asserted-by":"crossref","unstructured":"Massie BM, Carson PE, McMurray JJ, Komajda M, McKelvie R, Zile MR et al. Irbesartan in Patients with Heart Failure and Preserved Ejection Fraction. New England Journal of Medicine. 2008;359(23):2456\u201367. DOI: 10.1056\/NEJMoa0805450","DOI":"10.1056\/NEJMoa0805450"},{"key":"ref27","doi-asserted-by":"crossref","unstructured":"Yusuf S, Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJ et al. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. The Lancet. 2003;362(9386):777\u201381. DOI: 10.1016\/S0140-6736(03)14285-7","DOI":"10.1016\/S0140-6736(03)14285-7"},{"key":"ref28","unstructured":"Svirida O.N., Ovchinnikov A.G., Ageev F.T. Influence of candesartan and its combination with spironolactone on left ventricular diastolic function and level of collagen balance\u2019s biochemical markers in patients with chronic heart failure and preserved left ventricular systolic function. Russian Heart Failure Journal. 2010;11(5):263-75."},{"key":"ref29","doi-asserted-by":"crossref","unstructured":"Edelmann F, Wachter R, Schmidt AG, Kraigher-Krainer E, Colantonio C, Kamke W et al. Effect of Spironolactone on Diastolic Function and Exercise Capacity in Patients With Heart Failure With Preserved Ejection Fraction: The Aldo-DHF Randomized Controlled Trial. JAMA. 2013;309(8):781\u201391. DOI: 10.1001\/jama.2013.905","DOI":"10.1001\/jama.2013.905"},{"key":"ref30","doi-asserted-by":"crossref","unstructured":"Pitt B, Pfeffer MA, Assmann SF, Boineau R, Anand IS, Claggett B et al. Spironolactone for Heart Failure with Preserved Ejection Fraction. New England Journal of Medicine. 2014;370(15):1383\u201392. DOI: 10.1056\/NEJMoa1313731","DOI":"10.1056\/NEJMoa1313731"},{"key":"ref31","doi-asserted-by":"crossref","unstructured":"Pfeffer MA, Braunwald E. Treatment of Heart Failure with Preserved Ejection Fraction: Reflections on Its Treatment with an Aldosterone Antagonist. JAMA Cardiology. 2016;1(1):7\u20138. DOI: 10.1001\/jamacardio.2015.0356","DOI":"10.1001\/jamacardio.2015.0356"},{"key":"ref32","unstructured":"Uppsala University. Spironolactone Initiation Registry Randomized Interventional Trial in Heart Failure With Preserved Ejection Fraction, SPIRRIT-HFPEF. ClinicalTrials.gov ID: NCT02901184. Av. at: https:\/\/clinicaltrials.gov\/ct2\/show\/study\/NCT02901184. 2021."},{"key":"ref33","doi-asserted-by":"crossref","unstructured":"Solomon SD, McMurray JJV, Anand IS, Ge J, Lam CSP, Maggioni AP et al. Angiotensin\u2013Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction. New England Journal of Medicine. 2019;381(17):1609\u201320. DOI: 10.1056\/NEJMoa1908655","DOI":"10.1056\/NEJMoa1908655"},{"key":"ref34","doi-asserted-by":"crossref","unstructured":"Anker SD, Butler J, Filippatos G, Ferreira JP, Bocchi E, B\u00f6hm M et al. Empagliflozin in Heart Failure with a Preserved Ejection Fraction. New England Journal of Medicine. 2021;385(16):1451\u201361. DOI: 10.1056\/NEJMoa2107038","DOI":"10.1056\/NEJMoa2107038"},{"key":"ref35","doi-asserted-by":"crossref","unstructured":"Gevaert AB, Kataria R, Zannad F, Sauer AJ, Damman K, Sharma K et al. Heart failure with preserved ejection fraction: recent concepts in diagnosis, mechanisms and management. Heart. 2022; heartjnl-2021-319605. [Epub ahead of print]. DOI: 10.1136\/heartjnl-2021-319605","DOI":"10.1136\/heartjnl-2021-319605"},{"key":"ref36","doi-asserted-by":"crossref","unstructured":"Ferreira JP, Butler J, Zannad F, Filippatos G, Schueler E, Steubl D et al. Mineralocorticoid Receptor Antagonists and Empagliflozin in Patients with Heart Failure and Preserved Ejection Fraction. Journal of the American College of Cardiology. 2022;79(12):1129\u201337. DOI: 10.1016\/j.jacc.2022.01.029","DOI":"10.1016\/j.jacc.2022.01.029"},{"key":"ref37","doi-asserted-by":"crossref","unstructured":"Heidenreich PA, Bozkurt B, Aguilar D, Allen LA, Byun JJ, Colvin MM et al. 2022 AHA\/ACC\/HFSA Guideline for the Management of Heart Failure. Journal of the American College of Cardiology. 2022;79(17):e263\u2013421. DOI: 10.1016\/j.jacc.2021.12.012","DOI":"10.1016\/j.jacc.2021.12.012"},{"key":"ref38","unstructured":"\u041e\u0432\u0447\u0438\u043d\u043d\u0438\u043a\u043e\u0432 \u0410.\u0413., \u0411\u0430\u043b\u0434\u0438\u043d\u0430 \u041e.\u041d., \u0421\u0435\u0440\u0431\u0443\u043b \u0412.\u041c., \u0410\u0433\u0435\u0435\u0432 \u0424.\u0422. \u0410\u043b\u044c\u0434\u043e\u0441\u0442\u0435\u0440\u043e\u043d \u2013 \u043e\u0434\u0438\u043d \u0438\u0437 \u043e\u0441\u043d\u043e\u0432\u043d\u044b\u0445 \u0444\u0430\u043a\u0442\u043e\u0440\u043e\u0432 \u0441\u0442\u0438\u043c\u0443\u043b\u044f\u0446\u0438\u0438 \u0444\u0438\u0431\u0440\u043e\u0437\u0430. \u041c\u043e\u0436\u043d\u043e \u043b\u0438 \u0441 \u044d\u0442\u0438\u043c \u0431\u043e\u0440\u043e\u0442\u044c\u0441\u044f? \u0410\u0442\u043c\u043e\u0441\u0444\u0435\u0440\u0430 \u043a\u0430\u0440\u0434\u0438\u043e\u043b\u043e\u0433\u0438\u044f. 2005;3:12-9"}],"container-title":["Kardiologiia"],"original-title":[],"link":[{"URL":"https:\/\/lib.ossn.ru\/jour\/article\/viewFile\/2233\/1249","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T17:16:20Z","timestamp":1793639780000},"score":1,"resource":{"primary":{"URL":"https:\/\/cardio.elpub.ru\/jour\/article\/view\/2233"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,31]]},"references-count":38,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2022,7,31]]}},"URL":"https:\/\/doi.org\/10.18087\/cardio.2022.7.n2233","relation":{},"ISSN":["2412-5660","0022-9040"],"issn-type":[{"value":"2412-5660","type":"electronic"},{"value":"0022-9040","type":"print"}],"subject":[],"published":{"date-parts":[[2022,7,31]]}}}